Form 4: Recursion Pharmaceuticals CFO Michael Secora Executes Stock Options and Sells Shares Under 10b5-1 Plan

Michael Secora, CFO of Recursion Pharmaceuticals, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Summary

• On October 8 and 9, 2024, Michael Secora, the CFO of Recursion Pharmaceuticals, exercised stock options to acquire 39,375 shares of Class A Common Stock on each day at a price of $2.22 per share.
• Simultaneously, Secora sold 15,000 shares of Class A Common Stock on each day, with weighted average sale prices of $6.3171 on October 8 and $6.3583 on October 9.
• These transactions were executed under a 10b5-1 trading plan adopted by Secora on March 1, 2024.
• Following these transactions, Secora directly owns 1,450,881 shares of Class A Common Stock and holds options to purchase a significant number of additional shares at various exercise prices and vesting schedules.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, but the sale of shares could be perceived negatively by some investors. The large number of shares still held by the CFO is a positive sign.

Positives

• The transactions are part of a pre-arranged 10b5-1 trading plan, suggesting they were planned well in advance and not based on recent insider information.

Negatives

• The sale of shares by the CFO could be interpreted negatively by some investors, although it is part of a pre-planned strategy.

Risks

• There is always a risk that insider sales, even under a 10b5-1 plan, could be perceived negatively by the market and potentially impact the stock price.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid insider trading concerns. Investors often monitor these transactions for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also see regular filings of Form 4 documents related to executive stock transactions.
• The vesting schedules and exercise prices of the stock options are typical for executive compensation packages in the industry.

Stakeholder Impact

• The transactions could have a minor impact on shareholders depending on how they interpret the CFO's stock sales.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates